RT Journal Article
SR Electronic
T1 Immunophenotyping and machine learning identify distinct immunotypes that predict COVID-19 clinical severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.07.21256531
DO 10.1101/2021.05.07.21256531
A1 Yvonne M. Mueller
A1 Thijs J. Schrama
A1 Rik Ruijten
A1 Marco W.J. Schreurs
A1 Dwin G.B. Grashof
A1 Harmen J. G. van de Werken
A1 Daniel Alvarez de la Sierra
A1 Caoimhe H. Kiernan
A1 Melisa D. Castro Eiro
A1 Marjan van Meurs
A1 Inge Brouwers-Haspels
A1 Manzhi Zhao
A1 Ling Li
A1 Harm de Wit
A1 Christos A. Ouzounis
A1 Merel E. P. Wilmsen
A1 Tessa Alofs
A1 Danique A. Laport
A1 Tamara van Wees
A1 Geoffrey Kraker
A1 Maria C. Jaimes
A1 Sebastiaan Van Bockstael
A1 Manuel Hernández-González
A1 Casper Rokx
A1 Bart J.A. Rijnders
A1 Ricardo Pujol-Borrell
A1 Peter D. Katsikis
YR 2021
UL http://medrxiv.org/content/early/2021/05/09/2021.05.07.21256531.abstract
AB Quantitative or qualitative differences in immunity may drive and predict clinical severity in COVID-19. We therefore measured modules of serum pro-inflammatory, anti-inflammatory and anti-viral cytokines in combination with the anti-SARS-CoV-2 antibody response in COVID-19 patients admitted to tertiary care. Using machine learning and employing unsupervised hierarchical clustering, agnostic to severity, we identified three distinct immunotypes that were shown post-clustering to predict very different clinical courses such as clinical improvement or clinical deterioration. Immunotypes did not associate chronologically with disease duration but rather reflect variations in the nature and kinetics of individual patient’s immune response. Here we demonstrate that immunophenotyping can stratify patients to high and low risk clinical subtypes, with distinct cytokine and antibody profiles, that can predict severity progression and guide personalized therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Health Holland LSHM20056 grant (PDK), and in part supported by the Erasmus foundation (BJAR), grant PI20/00416 from the Instituto de Salud Carlos III (RPB) and the European Regional Development Fund (ERDF) (RPB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients were included in this study after ethical approval from the respective institutional ethics committees. Rotterdam cohort: The study was reviewed and approved by the institutional review board of the Erasmus University Medical Center. Written informed consent was obtained from every patient or legal representative. Barcelona cohort: The study was reviewed and approved by the Ethics Committee for Research with Medicines of the University Hospital Vall d'Hebron. Written informed consent was obtained from every patient or legal representative. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study are available on request from the corresponding author PDK. The data are not publicly available due to participant privacy/consent.